Antengene Announces Acceptance of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study

Dec 07, 2020View PDF

Shanghai and Hong Kong, PRC, December 7, 2020– Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for ATG-010 (selinexor) combined with R-GDP (SR-GDP) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). The trial is a global Phase 2/3, multicenter, randomized study aiming to evaluate the safety and efficacy of ATG-010 in combination with R-GDP (SR-GDP) in patients with rrDLBCL (Code: XPORT-DLBCL-030).

ATG-010 is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc. (NASDAQ: KPTI). In July 2019, the US Food and Drug Administration (FDA) approved ATG-010 in combination with low-dose dexamethasone for the treatment of relapsed/refractory multiple myeloma (rrMM). After its initial approval of rrMM, FDA approved ATG-010 as a single-agent for the treatment of rrDLBCL in June 2020. In China, Antengene is conducting a registrational Phase 2 clinical trial to evaluate the efficacy and safety of ATG-010 in the treatment of patients with rrDLBCL who have received at least 2 but no more than 5 previous systemic regimens and the first patient was dosed in April 2020.

The Phase 2 part of the study aims to identify the optimal dose of ATG-010 (40mg or 60mg) in combination with R-GDP and will also evaluate the SR-GDP regimen against an active R-GDP comparator arm. The Phase 3 part of the study contains three arms and aims to evaluate the selected optimal dose of ATG-010 in combination with R-GDP for up to 6 cycles followed by continuous ATG-010 (SR-GDP→S) until disease progression versus the selected optimal dose of ATG-010 in combination with R-GDP for up to 6 cycles followed by placebo (SR-GDP→P) until disease progression and versus standard R-GDP with matching placebo for up to 6 cycles followed by placebo (PR-GDP→P) until disease progression. The study will be conducted at multiple international centers across 11 countries, located in China, U.S., Europe, Australia and other locations. Up to 501 patients will be enrolled and treated in the Phase 2/3 study.

“The submission of NDAs for ATG-010 in multiple APAC markets in the past few weeks has marked a significant milestone for Antengene as our lead product candidate, ATG-010, advances towards commercial stage. This IND acceptance of ATG-010 in a new therapy for rrDLBCL marks another important milestone for Antengene, demonstrating our commitment to bringing innovative oncology therapies to cancer patients worldwide.” Dr. Jay Mei, Founder, Chairman and CEO of Antengene, commented, “We look forward to harnessing the power of Antengeners to extend the lives and improve the quality of life of patients by discovering, developing and commercializing novel therapies.”

About ATG-010 (selinexor, XPOVIO®)

ATG-010 (selinexor, XPOVIO®) is a first-in-class and only-in-class oral selective inhibitor of nuclear export compound, developed by Antengene and Karyopharm Therapeutics Inc. (NASDAQ: KPTI). In July 2019, the US Food and Drug Administration (FDA) approved ATG-010 in combination with low-dose dexamethasone for the treatment of relapsed/refractory multiple myeloma (rrMM) and in June 2020 approved ATG-010 as a single-agent for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL). ATG-010 is so far the first and only oral SINE compound approved by the FDA. ATG-010 is also being evaluated in several other mid-and later-phase clinical trials across multiple solid tumor indications, including liposarcoma and endometrial cancer. In November 2020, at the Connective Tissue Oncology Society 2020 Annual Meeting (CTOS 2020), Antengene’s partner, Karyopharm Therapeutics, presented positive results from the Phase 3 randomized, double blind, placebo controlled, cross-over SEAL study evaluating single agent, oral ATG-010 versus matching placebo in patients with liposarcoma. Karyopharm also recently announced that the ongoing Phase 3 SIENDO study of ATG-010 in patients with endometrial cancer passed planned interim futility analysis and that Data and Safety Monitoring Board (DSMB) recommended the study should proceed as planned without any modifications. Top-line SIENDO study results are expected in the second half of 2021.

Antengene is conducting two registrational Phase 2 clinical trials of ATG-010 in China for relapsed refractory multiple myeloma (MARCH) and for relapsed refractory diffuse large B-cell lymphoma (SEARCH), and has initiated clinical trials for high prevalence cancer types in the Asia Pacific region including peripheral T-cell lymphoma and NK/T-cell lymphoma (TOUCH) and KRAS-mutant non-small cell lung cancer (TRUMP).

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 10 investigational new drug approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. The vision of Antengene is to “Treat Patients Beyond Borders”. Antengene aims to address significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

XPORT-DLBCL-030 was initiated by Karyopharm Therapeutics Inc.;
XPOVIO® is a registered trademark of Karyopharm Therapeutics Inc.;
R-GDP: Rituximab, Gemcitabine, Dexamethasone and Cisplatin.